Since PPARγ agonists induce storage of fatty acids and glucose rather than consumption in the cell, the dual activation of PPARα and PPARγ is proposed to be more beneficial in managing metabolic diseases such as dyslipidemia of diabetes and fatty liver. Here, PPARG is linked to diabetes mellitus.